Cencora, Inc.
corporate_fare Company Profile
Cencora, Inc. (NYSE:COR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for COR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for COR spans 8-K, 10-Q.
Recent high-impact activity:
- FTC Sues to Block $3.5B Cencora Vet-Unit Sale to Covetrus
- Cencora Recasts Financials Into Three New Segments Starting Fiscal 2027
- Cencora Beats on Q4 Adjusted EPS of $4.66, Guides FY27 to $19.40-$19.75 and Raises Dividend 10%
- Cencora Posts $2.71 Q4 EPS as Drug Distributor Closes Fiscal Year
- Cencora to Buy American Oncology Network for $2.4B Enterprise Value; Lifts FY26 EPS View
Financial Snapshot
Short Interest & Short Volume
2.60 days to coverFINRA reported short interest of 3,155,491 shares in COR as of the October 30, 2026 settlement, a 19.7% decrease from the prior period — about 2.6 days to cover at its recent average daily volume. On November 20, 2026, 68.3% of COR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.